Simon Dingemans Purchases 7 Shares of GlaxoSmithKline plc (GSK) Stock
GlaxoSmithKline plc (LON:GSK) insider Simon Dingemans purchased 7 shares of the business’s stock in a transaction that occurred on Tuesday, October 11th. The stock was bought at an average cost of GBX 1,728 ($21.39) per share, with a total value of £120.96 ($149.70).
GlaxoSmithKline plc (LON:GSK) opened at 1700.00 on Friday. The company’s 50 day moving average price is GBX 1,649.81 and its 200-day moving average price is GBX 1,561.10. GlaxoSmithKline plc has a 12-month low of GBX 1,277.25 and a 12-month high of GBX 1,745.56. The stock’s market cap is GBX 82.64 billion.
The firm also recently disclosed a dividend, which was paid on Thursday, October 13th. Investors of record on Thursday, August 11th were paid a dividend of GBX 19 ($0.24) per share. The ex-dividend date of this dividend was Thursday, August 11th. This represents a yield of 1.12%.
Several research firms recently commented on GSK. BNP Paribas reaffirmed a “neutral” rating and issued a GBX 1,560 ($19.31) price target on shares of GlaxoSmithKline plc in a report on Thursday, August 4th. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research report on Tuesday, July 19th. Liberum Capital reiterated a “buy” rating and issued a GBX 1,900 ($23.51) price objective on shares of GlaxoSmithKline plc in a research report on Tuesday, September 20th. Deutsche Bank AG reiterated a “hold” rating and issued a GBX 1,800 ($22.28) price objective on shares of GlaxoSmithKline plc in a research report on Friday, September 2nd. Finally, Citigroup Inc. reiterated a “buy” rating on shares of GlaxoSmithKline plc in a research report on Wednesday, July 27th. Three investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of GBX 1,687.13 ($20.88).
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.